Not A Member?       Forget Password?
          Click HERE                   Click HERE
   and Register FREE
Fibrocell Science, Inc.
( :FCSC ) / David Pernock
diaDexus, Inc.
( OTCBB:DDXS ) / Dr. Brian Ward
NovaBay Pharmaceuticals, Inc.
( NYSE:NBY ) / Ron Najafi, Ph.D. Thomas Paulson, M.B.A.
EnerJex Resources, Inc.
( OTCBB:ENRJ ) / Robert Watson, Jr. Atticus Lowe
League Now Holdings Corporation (Infiniti Systems Group, Inc.)
( OTCBB:LNWZ ) / Mr. John L. Bianco Mr. D. Bruce Veness
Sunshine Biopharma, inc.
( OTCBB:SBFM ) / Steve N. Slilaty Camille Sebaaly
TheraBiogen, Inc.
( OTCBB:TRAB ) / Kelly Hickel
Trimedyne, Inc.
( OTCBB:TMED ) / Marvin P. Loeb
XsunX Inc.
( OTCBB:XSNX ) / Mr. Tom M. Djokovich
Ausust 3rd, 2015 CEOcast Weekly Newsletter
Companies featured in this edition of the newsletter: IMNP This week the stock market ended on a cautious note, equities held modest gains at the start thanks to a pre market jump in the futures m... Click here for more...

Kindred Biosciences, Inc.
Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.
Immune Pharmaceuticals, Inc.

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops and commercializes targeted therapeutics for the treatment of inflammatory diseases and cancer. The company's lead product candidate is Bertilimumab, a human monoclonal antibody, which is under Phase II clinical trial for the treatment of ulcerative colitis, bullous pemphigoid, and Crohn's disease. It is also developing AmiKet, a prescription topical analgesic cream, which is in Phase III clinical trial to treat peripheral neuropathies; NanomAbs technology platform, an antibody-drug conjugate platform for the treatment of cancer; and Crolibulin, a novel small molecule vascular disruption agent and apoptosis inducer, which is under Phase I/II clinical trials for the treatment of patients with solid tumors. The company has license, and other collaborative research and development arrangements with iCo Therapeutics Inc.; Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.; MabLife SAS; Lonza Sales AG; Dalhousie University; Shire Biochem, Inc.; and Endo Pharmaceuticals. The company was founded in 2010 and is headquartered in New York, New York.


Copyright © 2001-2015. All Rights Reserved. Disclaimer | Privacy Policy